Nello Mainolfi

Founder and Chief Technology Officer
Kymera Therapeutics
Nina E. Weisser
Nello Mainolfi, PhD Founder & Chief Scientific Officer, Kymera Therapeutics Before founding Kymera, Nello was head of drug discovery at Raze Therapeutics (an Atlas portfolio company) where he helped develop first in class molecules against novel cancer metabolism targets with implications in both oncology and immuno-metabolism. Nello started his drug discovery career in the global discovery chemistry group at the Novartis Institutes for Biomedical Research, where he contributed and, in most cases, led teams to the identification of more than 10 compounds that have entered preclinical and clinical development across a series of disease areas, notably first in class small molecules inhibitors of several complement proteins for inflammation and ocular diseases. While at Novartis he also championed new technologies such as using fragment-based drug discovery as a core strategy to deliver multiple development candidates. Nello has authored >40 papers and patents and has written reviews in the areas of medicinal chemistry and drug discovery. Nello was trained at Imperial College, University of London and The Scripps Research Institute in California.


No data was found